Breakthrough in SSTR2-Targeted ADC

At the 2025 AACR (American Association for Cancer Research) Annual Meeting, CStone Pharmaceuticals unveiled preclinical data for its SSTR2-targeted antibody-drug conjugate (ADC), CS5005, for the first time. The data revealed potent antitumor activity in neuroendocrine tumor (NET) and small cell lung cancer (SCLC) models. Notably, the research team systematically verified the drug’s target-dependent effect by constructing both high-expression (NCI-H524) and low-expression (NCI-H446, NCI-H69) SSTR2 in vitro and in vivo models—setting a new benchmark for precision ADC development!

SSTR2: The “Hidden Switch” in Targeted Cancer Therapy

Somatostatin receptor 2 (SSTR2) is a member of the G protein-coupled receptor family and plays a regulatory role in cell proliferation, secretion, and metabolism. Under normal physiological conditions, SSTR2 is highly expressed in the pituitary, pancreas, and gastrointestinal neuroendocrine cells. In pathological states, however, its abnormal overexpression has become a hallmark of malignant tumors such as neuroendocrine tumors (NET) and small cell lung cancer (SCLC).

In recent years, the value of SSTR2 as a drug target has been redefined—its high internalization efficiency and tumor-specific expression make it an ideal ADC target. However, accurately distinguishing between target-specific cytotoxicity and off-target toxicity remains a major challenge in drug development.

SSTR2-ADC Development: From “Me Too” to Smart Innovation

Globally, the SSTR2-ADC race is heating up. Besides CStone’s CS5005, industry giants like Novartis and AstraZeneca are also developing in this space. Current R&D focus areas include:

Improving targeting precision: Screening novel antibodies to reduce binding to normal tissues
Optimizing linker-payload strategies: Balancing potency and safety (e.g., using topoisomerase inhibitors)
Expanding indications: Exploring combination therapies for tumors with low or moderate SSTR2 expression (e.g., with immune checkpoint inhibitors)
Multi-target combinations: Addressing tumor heterogeneity to overcome the limitations of single-target therapies

The “Golden Key” to Validating ADC Efficacy

To address the high heterogeneity of the SSTR2 target, Kyinno Biotechnology, Inc., leveraging its robust engineered cell development capabilities, has built four classic model types. Backed by platforms for antibody discovery and in vivo/in vitro pharmacology services, Kyinno provides full-process, target-centric solutions. Contact us for more information.

High SSTR2 expression model (NCI-H524): Used to assess ADC internalization, payload release, and direct cytotoxicity
Low SSTR2 expression models (NCI-H446, NCI-H69) and knockout model (NCI-H524-SSTR2-KO): Represent tumor heterogeneity in SCLC and are used to validate target specificity and bystander effects
SSTR2 overexpression models (CHOK1/293-SSTR2-OE): Evaluate antibody affinity of ADCs
SSTR2 knockout control model (293-SSTR2-KO): Utilizes the AB5000 off-targeting platform to exclude non-target-related toxicity and ensure data reliability

The rise of SSTR2-targeted ADCs marks the beginning of a “precision conjugation” era in oncology. Systematic use of high/low expression models not only sets a gold standard for efficacy evaluation but also optimizes drug design at its core. Looking ahead, as pan-cancer expression databases grow and multi-omics integration technologies mature, SSTR2-ADCs are expected to break through current indication limitations and benefit a broader patient population.